Evidence map›Paper›PMID 33403362›Full record

ArticleJACC. CardioOncology2020

Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial.

Roberto Bolli, Emerson C Perin, James T Willerson, Phillip C Yang, Jay H Traverse, Timothy D Henry, Carl J Pepine, Raul D Mitrani, Joshua M Hare, Michael P Murphy and 25 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Internalization of transferrin-taggedExperimental biology and medicine (Maywood, N.J.) · 2024
    Article
  14. Review
  15. New treatment methods for myocardial infarction.Frontiers in cardiovascular medicine · 2023
    Review
  16. Article
  17. CD4Aging and disease · 2022
    Article
  18. Article
  19. Review
  20. Novel Therapeutics for Anthracycline Induced Cardiotoxicity.Frontiers in cardiovascular medicine · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 17 institutions in 1 country.

Roberto BolliDepartment of Medicine, Division of Cardiovascular Medicine, University of Louisville, School of Medicine, Louisville, Kentucky, USA.
Emerson C PerinDivision of Cardiology Research, Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, USA.
James T WillersonDivision of Cardiology Research, Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, USA.
Phillip C YangDepartment of Medicine and Cardiovascular Institute, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
Jay H TraverseDepartment of Medicine, Cardiovascular Division, Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, and University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
Timothy D HenryThe Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, Ohio, USA.
Carl J PepineDepartment of Medicine, Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
Raul D MitraniDepartment of Medicine, Cardiovascular Division, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Joshua M HareDepartment of Molecular and Cellular Pharmacology, Division of Cardiology, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Michael P MurphyDepartment of Surgery, Division of Vascular Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Keith L MarchDepartment of Medicine, Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
Sohail IkramDepartment of Medicine, Division of Cardiovascular Medicine, University of Louisville, School of Medicine, Louisville, Kentucky, USA.
David P LeeDepartment of Medicine and Cardiovascular Institute, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
Connor O'BrienDepartment of Medicine and Cardiovascular Institute, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
Jean-Bernard DurandDepartment of Cardiology, Division of Internal Medicine, M.D. Anderson Cancer Center, Houston, Texas, USA.
Kathy MillerDepartment of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Joao A LimaDepartment of Medicine, Cardiology Division, Johns Hopkins University, Baltimore, Maryland, USA.
Mohammad R OstovanehDepartment of Medicine, Cardiology Division, Johns Hopkins University, Baltimore, Maryland, USA.
Bharath Ambale-VenkateshDepartment of Medicine, Cardiology Division, Johns Hopkins University, Baltimore, Maryland, USA.
Adrian P GeeDepartment of Pediatrics, Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.
Sara RichmanDepartment of Pediatrics, Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.
Doris A TaylorDepartment of Regenerative Medicine Research, Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, USA.
Shelly L SayreDepartment of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
Judy BettencourtDepartment of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
Rachel W VojvodicDepartment of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
Michelle L CohenDepartment of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
Lara M SimpsonDepartment of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
Dejian LaiDepartment of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
David AguilarDepartment of Epidemiology, Human Genetics and Environmental Sciences, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
Catalin LoghinDepartment of Medicine, Division of Cardiovascular Medicine, UTHealth University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA.
Lem MoyéDepartment of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
Ray F EbertDivision of Cardiovascular Sciences, Basic & Early Translational Research Program, National Institutes of Health, National Heart, Lung, and Blood Institute, Washington, DC, USA.
Barry R DavisDepartment of Biostatistics & Data Science, UTHealth University of Texas Health Science Center at Houston School of Public Health, Houston, Texas, USA.
Robert D SimariDivision of Cardiovascular Diseases, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Cardiovascular Cell Therapy Research Network (CCTRN)
The University of Texas Health Science Center at Houston · USBaylor College of Medicine · USCardiovascular Institute of the South · USJohns Hopkins University · USUniversity of Louisville · USUniversity of Miami · USChrist Hospital · USFlorida College · USIndiana University – Purdue University Indianapolis · USIndiana University School of MedicineJohns Hopkins Medicine · USNational Heart Lung and Blood Institute · USPediatrics and Genetics · USStanford University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Florida · USUniversity of Minnesota · US

Funding

Data Coordinating Center For The Cardiovascular Cell Therapy Research NetworkUM1HL087318 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DAVIS, BARRY R · 2012 to 2018
$29.8M
Using Exosomes to Preserve Viability and Function in Anthracycline Induced Cardiomyopathy Patient Specific Cardiomyocytes After Exposure to DoxorubicinF32HL139046 · NHLBI · STANFORD UNIVERSITY · PI O'BRIEN, CONNOR · 2017 to 2018
$126k
NHLBI NIH HHS F32 HL139046NHLBI NIH HHS UM1 HL087318
6 · The paper itself

Abstract

backgroundAnthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) is a promising approach to heart failure (HF) treatment.

objectivesSENECA (Stem Cell Injection in Cancer Survivors) was a phase 1 study of allo-MSCs in AIC.

methodsCancer survivors with chronic AIC (mean age 56.6 years; 68% women; NT-proBNP 1,426 pg/ml; 6 enrolled in an open-label, lead-in phase and 31 subjects randomized 1:1) received 1 × 10

resultsA total of 97% of subjects underwent successful study product injections; all allo-MSC-assigned subjects received the target dose of cells. Follow-up visits were well-attended (92%) with successful collection of endpoints in 94% at the 1-year visit. Although 58% of subjects had non-CMR compatible devices, CMR endpoints were successfully collected in 84% of subjects imaged at 1 year. No new tumors were reported. There were no significant differences between allo-MSC and vehicle groups with regard to clinical outcomes. Secondary measures included 6-min walk test (p = 0.056) and Minnesota Living with Heart Failure Questionnaire score (p = 0.048), which tended to favor the allo-MSC group.

conclusionsIn this first-in-human study of cell therapy in patients with AIC, transendocardial administration of allo-MSCs appears safe and feasible, and CMR was successfully performed in the majority of the HF patients with devices. This study lays the groundwork for phase 2 trials aimed at assessing efficacy of cell therapy in patients with AIC.

Indexed as

cardiac repaircardiooncologychemotherapyheart failurestem cells

Identifiers

PMID33403362
PMCPMC7781291
OpenAlexW3090560470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.